OncoMatch/Clinical Trials/NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Is NCT07216703 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for cervical cancer.
Treatment: Pembrolizumab · Sacituzumab Tirumotecan · Bevacizumab · Paclitaxel · Cisplatin · Carboplatin · Rescue Medications — Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) expression (CPS ≥1)
tumor programmed cell death ligand 1 expression of combined positive score ≥1
Disease stage
Required: Stage FIGO-2028 STAGE IVB (other)
Metastatic disease required
persistent, recurrent, or newly diagnosed metastatic (International Federation of Gynecology and Obstetrics [FIGO]-2028 Stage IVB) cervical cancer that is not amenable to curative treatment (surgery and/or radiation)
Performance status
ECOG 0–1(Restricted strenuous activity)
Eastern Cooperative Oncology Group performance status of 0 or 1
Demographics
Prior therapy
Cannot have received: systemic anticancer therapy
Exception: other than what is specified in this protocol
Has received prior systemic anticancer therapy other than what is specified in this protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mount Sinai Comprehensive Cancer Center ( Site 6000) · Miami Beach, Florida
- Florida Cancer Specialists - East ( Site 7000) · West Palm Beach, Florida
- Winship Cancer Institute of Emory University ( Site 5005) · Atlanta, Georgia
- Nancy N. & J.C. Lewis Cancer and Research Pavillion - Research Department ( Site 6005) · Savannah, Georgia
- TRIALS 365 ( Site 6008) · Shreveport, Louisiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07216703 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage FIGO-2028 STAGE IVB is required (metastatic disease required).
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages